Abstract
Over the last two decades, the medical community witnessed an
outstanding and accelerated development on minimally invasive therapies.
With the dorsal spine of supportive data from large randomized control
trials, transcatheter aortic valve replacement (TAVR), aortic and mitral
valve-in-valve, mechanical circulatory support and peripheral
endovascular interventions all share the need of accessing a vascular
bed with a large bore catheter. Nevertheless, to date, there has yet to
be a universal consensus on defining large-bore vascular access (LBVA)
in the world of transcatheter therapies. We explore the evolution,
characteristics and vascular compatibility of the current commercially
available devices, analyze the devices along with access site-specific
complications rates and finally review the present methods for
percutaneous vascular closure.